ArticleClinical neuroradiology2025
The DERIVO 2 Heal Embolization Device in the Treatment of Ruptured and Unruptured Intracranial Aneurysms: a Retrospective Multicenter Study.
Article in Clinical neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Non-Ischemic Cerebral Enhancing (NICE) lesions after flow diversion for intracranial aneurysms: a systematic review with case-level synthesis.BMC neurology · 2026Pooled it
- Single antiplatelet therapy and tirofiban bridged with surface modified flow diverters for ruptured blood blister-like aneurysms: single center experience and systematic review.Journal of neurointerventional surgery · 2026Pooled it
- Defining biomaterial-driven design principles for bioabsorbable flow diverters: current state and perspectives.Bioactive materials · 2027Review
- Incidence of Fish-mouthing and Wall Malapposition of Different Flow Diverters in the Treatment of Cerebral Aneurysms: Device-specific Findings in a Retrospective Single-center Analysis.Clinical neuroradiology · 2026Article
- Comparative hemocompatibility assessment of fibrin/heparin-coated and PMEA-coated flow diverters.Journal of materials science. Materials in medicine · 2026Article
- In-Stent Stenosis After Surface-Modified Versus Uncoated Flow Diversion: a Randomized Trial (Derivo 2 Heal vs Derivo 2).Clinical neuroradiology · 2026Article
- Preliminary study on optimizing head position for endovascular treatment of anterior communicating artery aneurysms.Frontiers in neuroscience · 2026Article
- Aneurysm Specific Working Projections for the Endovascular Treatment of Intracranial Aneurysms-Same Aneurysm, Different Working Projections?"Cardiovascular and interventional radiology · 2025Article
- Endovascular Treatment of Ruptured and Unruptured Wide-Neck Intracranial Aneurysms Using LVIS EVO Stent-Assisted Coiling: Mid-Term Results.Journal of clinical medicine · 2025Article
- Efficacy and safety of Derivo embolization device in intracranial aneurysms: A systematic review and Meta-Analysis.Neuroradiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backroundThe use of flow diverting stents in the treatment of intracranial aneurysms is associated with a risk of neurological morbidity due to their thrombogenicity. To reduce this risk different surface modifications have been developed. The Derivo 2 Embolization Device (Acandis, Pforzheim, Germany) has proven to be a safe and effective flow diverter. To overcome the risk of thrombo-embolism, the device was modified by adding an anti-thrombogenic fibrin-heparin coating. We aimed to assess the safety and effectiveness of the Derivo 2 heal Embolization Device.
methodsRetrospective multicenter data from nine German neurovascular centers between February 2022 until December 2023 were used. Patients treated with the Derivo 2 heal Embolization Device for unruptured or ruptured intracranial aneurysms were included. Peri- and postprocedural adverse events, clinical outcomes, and angiographic follow-up results were evaluated.
results84 patients (73.8% female; mean age 58.7 years) with 89 aneurysms (mean size 9.8 mm) were included. 87.6% were located in the anterior circulation. Most of them were sidewall aneurysms (88.8%). 96 flow diverters were used. 99.0% were successfully implanted. An in-stent balloon angioplasty was performed in 6.0% of the cases. An additional coiling was performed in 28.6%. Technical difficulties were present in 12.0% of the cases. Thrombotic events occurred in 4.8% with no neurological sequelae. Mortality and morbidity were 0 and 1.2% respectively. Adequate aneurysm occlusion was achieved in 80.7% with a mean follow-up time of 6.6 months.
conclusionThe Derivo 2 heal Embolization Device showed a satisfying aneurysm occlusion and safety with a low rate of neurological morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.